{"date":"2025-09-18","count":13,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7729-2025-09-18-1737-13etwuy","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"17:37:38","subject":"本公司114年第一次現金增資股款催繳公告","clause":"第44款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2025-09-18 17:37，「本公司114年第一次現金增資股款催繳公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1786-2025-09-18-1733-1hjsbib","company_id":"1786","company":"科妍","market":"上市","industry":"生技醫療","date":"2025-09-18","time":"17:33:09","subject":"公告本公司一針劑型透明質酸”Flexotron Tendon”關節腔注射劑產品取得銷售許可證書","clause":"第51款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：科妍（1786），2025-09-18 17:33，「公告本公司一針劑型透明質酸”Flexotron Tendon”關節腔注射劑產品取得銷售許可證書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2025-09-18-1708-ixssj9","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"17:08:37","subject":"公告本公司114年第一次現金增資董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜","clause":"第37款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2025-09-18 17:08，「公告本公司114年第一次現金增資董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2025-09-18-1612-587n2p","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2025-09-18","time":"16:12:59","subject":"公告本公司董事會決議召開民國114年第一次股東臨時會","clause":"第17款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2025-09-18 16:12，「公告本公司董事會決議召開民國114年第一次股東臨時會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-09-18-1605-wt995l","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"16:05:02","subject":"補充公告本公司114年度現金增資發行新股之代收及專戶存儲價款行庫","clause":"第9款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-09-18 16:05，「補充公告本公司114年度現金增資發行新股之代收及專戶存儲價款行庫」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6580-2025-09-18-1558-1mgycxq","company_id":"6580","company":"台睿","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"15:58:57","subject":"公告本公司抗癌口服研發新藥CVM-1118用於治療中期肝癌，向中國國家藥品監督管理局提出第二期臨床試驗申請。","clause":"第44款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：台睿（6580），2025-09-18 15:58，「公告本公司抗癌口服研發新藥CVM-1118用於治療中期肝癌，向中國國家藥品監督管理局提出第二期臨床試驗申請。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6841-2025-09-18-1534-1aq7iqo","company_id":"6841","company":"長佳智能","market":"上櫃","industry":"生技醫療","date":"2025-09-18","time":"15:34:34","subject":"本公司受邀參加元大證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-09-25","cite_as":"公開資訊觀測站重大訊息：長佳智能（6841），2025-09-18 15:34，「本公司受邀參加元大證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-09-18-1507-vw9td3","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"15:07:16","subject":"台寶調整子公司持股結構以完備美國策略佈局","clause":"第9款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-09-18 15:07，「台寶調整子公司持股結構以完備美國策略佈局」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-09-18-1505-1c3jash","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"15:05:44","subject":"因應集團組織架構調整，董事會決議將原擬增資PhiBio Therapeutics Inc.改為增資Taiwan Bio Holding LLC","clause":"第17款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-09-18 15:05，「因應集團組織架構調整，董事會決議將原擬增資PhiBio Therapeutics Inc.改為增資Taiwan Bio 」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-09-18-1503-vw9td3","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"15:03:29","subject":"台寶調整子公司持股結構以完備美國策略佈局","clause":"第17款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-09-18 15:03，「台寶調整子公司持股結構以完備美國策略佈局」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-09-18-1500-ld0q70","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-09-18","time":"15:00:22","subject":"本公司自行撤回上櫃申請案，擬於明年重新申請掛牌","clause":"第44款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-09-18 15:00，「本公司自行撤回上櫃申請案，擬於明年重新申請掛牌」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4142-2025-09-18-1346-54swv6","company_id":"4142","company":"國光生","market":"上市","industry":"生技醫療","date":"2025-09-18","time":"13:46:51","subject":"公告本公司法人董事改派代表人","clause":"第6款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：國光生（4142），2025-09-18 13:46，「公告本公司法人董事改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2025-09-18-0056-1ieu8en","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2025-09-18","time":"00:56:59","subject":"本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之多國多中心樞紐三期CBL-0301(SUPREME-01)臨床試驗申請，美國FDA已核准執行。(更新說明預計收案時程)","clause":"第51款","fact_date":"2025-09-18","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2025-09-18 00:56，「本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之多國多中心樞紐三期CBL-0301(SUPREME-01)臨床試驗申」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}